

Pediatric CIRB Meeting Agenda

July 9, 2026

I. Amendment Review

AALL2321, A Phase 2 Study of Blinatumomab in Combination with Chemotherapy for Infants with Newly Diagnosed Acute Lymphoblastic Leukemia with Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax (Version Date 06/03/26)

II. Amendment Review

AAML1831, A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations (Version Date 05/08/26)

III. Amendment Review

ALTE11C2, Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy: A Limited Institution Non-Therapeutic Study (Version Date 06/03/26)

IV. Continuing Review

AAML18P1, Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP) (Version Date 10/06/20)

V. Continuing Review

ACCL2433, Risk-Based 6MP Adherence Enhancement Strategies in Children, Adolescent and Young Adults with ALL – A Pilot Study (Version Date 03/21/25)

VI. Continuing Review

ACNS1833, A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) (Version Date 08/28/25)

VII. Continuing Review

ARST2032, A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma (Version Date 12/05/22)

VIII. Continuing Review

PBTC-059, A Phase 1 Trial of Autologous HER2-specific CAR T cells in Pediatric Patients with Refractory or Recurrent Ependymoma (Version Date 03/20/26)

IX. Continuing Review

PEPN2011, A Phase 1/2 Study of Tegavivint (IND#156033, NSC#826393) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors (Version Date 02/13/23)
